MERTK and cancer: Dual AXL/MERTK inhibitors such as ONO-7475 [104,105,106], INCB081776 [107,108,109], CT413 [87], PF-07265807 [110], and Q702 [111,112], as well as pan-TAM inhibitors like RXDX-106 [40,113], BMS-777607 [114,115,116,117], and LDC1267 [88], have also been found to be effective in cancer models.